Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H20N4O2.ClH.H2O |
Molecular Weight | 354.832 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.[H][C@]12CC[C@]([H])(C[C@@H](C1)NC(=O)N3C(=O)NC4=CC=CC=C34)N2C
InChI
InChIKey=UZOZFPGVCIJZKM-NXNLNBCESA-N
InChI=1S/C16H20N4O2.ClH.H2O/c1-19-11-6-7-12(19)9-10(8-11)17-15(21)20-14-5-3-2-4-13(14)18-16(20)22;;/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,22);1H;1H2/t10-,11+,12-;;
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10378635Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8891590
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10378635
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8891590
DAU 6215 (Itasetron) is a selective 5-hydroxytryptamine3 (5-HT3) antagonist, which was developed by Boehringer Ingelheim. And was investigated for treatment the nausea and vomiting induced by chemotherapy, it was confirmed that this drug possessed antiemetic properties. Also was discovered, that chronic treatment with itasetron significantly improved retention abilities of the aged rats in this memory test. However, development of itasetron was terminated.
Originator
Sources: Retrived from http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1996.tb00297.x/full
Curator's Comment: # Boehringer Ingelheim Italia
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1695682 |
3.8 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10378635 |
Secondary | Unknown Approved UseUnknown |
||
Secondary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10378635
Nausea and vomiting: itasetron hydrochloride is effective in the dose range 35-280 microg/kg in preventing cisplatin-induced emesis.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1695682
DA 6215 (Itasetron ) has been synthesized and evaluated for 5-HT3 antagonistic activity in a radioligand binding assay. DA 6215 showed a Ki = 3.8 nM in the binding test
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30160727
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
904R36XZAJ
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY | |||
|
138602-61-6
Created by
admin on Fri Dec 15 15:56:46 GMT 2023 , Edited by admin on Fri Dec 15 15:56:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD